Analytical Data
-
Gene name
ERBB2
- Application
-
Biological Activity
Immobilized recombinant human ERBB2 at 10 ng/mL (100 μL/well) can bind Trastuzumab with a linearrange of 4- 20 ng/mL
-
Alternative Names
ERBB2；HER2；MLN19;Receptor tyrosine-Protein kinase erbB-2
-
Species
Human
-
Source
HEK293
-
Tag
C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P04626
-
Expression Region
23-652aa
-
Molecular Weight
100-120 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Identification
Protein Description
The ERBB2 (also known as HER2) gene encodes a member of the epidermal growth factor receptor (EGFR) family, which plays a crucial role in cell signaling pathways that regulate cell growth and differentiation. Overexpression of ERBB2 is frequently observed in various cancers, particularly in breast cancer, where it is associated with aggressive tumor behavior and poor prognosis. As a result, ERBB2 has become a significant target for therapeutic intervention. The development of monoclonal antibodies, such as trastuzumab (Herceptin), and small-molecule inhibitors has marked a breakthrough in targeted cancer therapy. However, resistance to these treatments remains a challenge, highlighting the need for further research into ERBB2’s role in tumor biology and potential novel therapeutic strategies. Recombination of the ERBB2 protein allows for the study of its functional properties and offers insights into receptor dimerization, signaling mechanisms, and interactions with other cellular components. Additionally, recombinant ERBB2 proteins can be utilized in the development of diagnostic tools and vaccines. Understanding the structural and functional aspects of ERBB2 through recombinant technology is vital for advancing personalized medicine approaches and improving clinical outcomes for patients with ERBB2-positive tumors.
